<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963976</url>
  </required_header>
  <id_info>
    <org_study_id>ICHADAPT513000128</org_study_id>
    <nct_id>NCT00963976</nct_id>
  </id_info>
  <brief_title>Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial</brief_title>
  <acronym>ICH ADAPT</acronym>
  <official_title>Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Heritage Foundation for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Management of blood pressure (BP) in the acute phase of intracerebral hemorrhage&#xD;
      (ICH) remains controversial. Although it has been established that there is a transient&#xD;
      moderate reduction of perihematoma cerebral blood flow (CBF) in acute ICH, the effect of BP&#xD;
      treatment is unknown. The potential for exacerbation of CBF has precluded routine aggressive&#xD;
      BP reduction.&#xD;
&#xD;
      Aim and Hypothesis: The primary study aim is to demonstrate the feasibility and safety of&#xD;
      acute BP reduction to &lt; 150 mmHg systolic using a standardized protocol in ICH patients. It&#xD;
      is hypothesized that CTP will not demonstrate evidence of perihematoma ischemia following&#xD;
      acute BP reduction.&#xD;
&#xD;
      Design: ICH ADAPT is a randomized blinded endpoint trial. Acutely hypertensive ICH patients&#xD;
      are randomized to a target systolic BP of &lt; 150 mmHg or &lt; 180 mmHg. Patients are treated with&#xD;
      intravenous (IV) labetalol/hydralazine/enalapril.&#xD;
&#xD;
      Study Outcomes: The primary outcome is cerebral blood flow in the perihematoma region,&#xD;
      measured with CT perfusion, 2 hours after randomization. Secondary outcomes include the&#xD;
      difference in BP at 1 and 2 hours post-randomization in the two treatment groups and hematoma&#xD;
      expansion rates at 24 hours.&#xD;
&#xD;
      Discussion: ICH ADAPT is the only randomized trial designed specifically to identify any&#xD;
      hemodynamic changes in the perihematoma region secondary to aggressive BP management. The&#xD;
      results of this trial will facilitate ongoing and future studies aimed at determining the&#xD;
      efficacy of rapid BP reduction in acute ICH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is cerebral blood flow in the perihematoma region, measured with CT perfusion, 2 hours after randomization.</measure>
    <time_frame>2 hours post randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematoma expansion rates at 24 hours.</measure>
    <time_frame>24 hours post randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Target systolic BP &lt; 150 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systolic blood pressure will be reduced to &lt;150 mmHg within 1 hour of randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Target systolic BP &lt; 180 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systolic blood pressure will be reduced, to &lt;180 mmHg within 1 hour of randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>labetalol/hydralazine/enalapril</intervention_name>
    <description>Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).</description>
    <arm_group_label>Target systolic BP &lt; 150 mmHg</arm_group_label>
    <arm_group_label>Target systolic BP &lt; 180 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Acute primary ICH demonstrated with CT scan&#xD;
&#xD;
          -  Onset ≤ 24 h prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to BP reduction i.e., severe arterial stenosis or high-grade stenotic&#xD;
             valvular heart disease&#xD;
&#xD;
          -  Indication for urgent BP reduction i.e., hypertensive encephalopathy, or aortic&#xD;
             dissection&#xD;
&#xD;
          -  Definite evidence that the ICH is secondary to underlying cerebral or vascular&#xD;
             pathology, i.e., AVM, aneurysm, tumour, trauma, vasculitis, or hemorrhagic&#xD;
             transformation of an ischemic infarct&#xD;
&#xD;
          -  Previous ischemic stroke within 30 days of current event NB: Prior ICH is not an&#xD;
             exclusion criterion&#xD;
&#xD;
          -  Planned surgical resection of hematoma NB: Extraventricular Drain placement is not an&#xD;
             exclusion criterion&#xD;
&#xD;
          -  Contraindication to CT perfusion imaging (i.e. contrast allergy, metformin use or&#xD;
             Creatinine &gt;160 μmol/l)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>February 24, 2012</last_update_submitted>
  <last_update_submitted_qc>February 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Ken Butcher</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cerebral Blood Flow</keyword>
  <keyword>CT Perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

